Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens

Pritsana Raungrut, Suchanan Tanyapattrapong, Thipphanet Masjon, Saowanee Maungchanburi, Paramee Thongsuksai, Peter C Hart · 2024

Read Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens by Pritsana Raungrut, Suchanan Tanyapattrapong, Thipphanet Masjon, Saowanee Maungchanburi, Paramee Thongsuksai, Peter C Hart (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11727171.txt.

Description

Lung cancer cells that resist drug pairs are profiled by Raungrut and co-authors in a 2024 study. The team grew two resistant lines from a human lung cancer line over six months of drug exposure. One line resists a platinum drug and the other a taxane drug, both used as a pair in care.

Gene scans found a shared set of changed genes across both lines. One gene, tied to cell growth signals, stood out as a hub. Checks in public data and lab tests support its value as a marker. If the marker holds in patients, it could help doctors judge who will gain from the drug pair and who needs another plan.

Catalog record

CREATORPritsana Raungrut, Suchanan Tanyapattrapong, Thipphanet Masjon, Saowanee Maungchanburi, Paramee Thongsuksai, Peter C Hart
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11727171

Browse the full library · About the Tower of Babel